Literature DB >> 29659732

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.

Selma Tobudic1, Christina Forstner1,2, Heinz Burgmann1, Heimo Lagler1, Michael Ramharter1,3, Christoph Steininger1, Matthias G Vossen1, Stefan Winkler1, Florian Thalhammer1.   

Abstract

The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29659732     DOI： 10.1093/cid/ciy279

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  32 in total

1.  Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.

Authors:  L Morata; J Cobo; M Fernández-Sampedro; P Guisado Vasco; E Ruano; J Lora-Tamayo; M Sánchez Somolinos; P González Ruano; A Rico Nieto; A Arnaiz; M Estébanez Muñoz; M E Jiménez-Mejías; A B Lozano Serrano; E Múñez; D Rodriguez-Pardo; R Argelich; A Arroyo; J M Barbero; F Cuadra; A Del Arco; M D Del Toro; L Guio; D Jimenez-Beatty; N Lois; O Martin; R M Martínez Alvarez; F J Martinez-Marcos; L Porras; M Ramírez; J Vergas García; A Soriano
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.

Authors:  Kyle C Molina; Matthew A Miller; Scott W Mueller; Edward T Van Matre; Martin Krsak; Tyree H Kiser
Journal:  Clin Pharmacokinet       Date:  2021-12-21       Impact factor: 5.577

Review 3.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

4.  Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.

Authors:  Selma Tobudic; Christina Forstner; Heinz Burgmann; Heimo Lagler; Christoph Steininger; Ludwig Traby; Mathias G Vossen; Stefan Winkler; Florian Thalhammer
Journal:  Infection       Date:  2019-09-13       Impact factor: 3.553

Review 5.  Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments.

Authors:  Asher Schranz; Joshua A Barocas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

6.  Effectiveness, safety and cost analysis of dalbavancin in clinical practice.

Authors:  Maria Arrieta-Loitegui; Jose Manuel Caro-Teller; Sara Ortiz-Pérez; Francisco López-Medrano; Rafael San Juan-Garrido; Jose Miguel Ferrari-Piquero
Journal:  Eur J Hosp Pharm       Date:  2020-10-05

Review 7.  Infective endocarditis - can we treat it more effectively?

Authors:  Aneta Guzek; Wojciech Braksator; Zbigniew Gąsior; Mariusz Kuśmierczyk; Jacek Różański; Zbigniew Rybicki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2020-04-08

Review 8.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

Review 9.  Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Authors:  Luis Buzón-Martín; I Zollner-Schwetz; Selma Tobudic; Emilia Cercenado; Jaime Lora-Tamayo
Journal:  Antibiotics (Basel)       Date:  2021-05-31

10.  Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis.

Authors:  Charlie Tan; Esfandiar Shojaei; Joshua Wiener; Meera Shah; Sharon Koivu; Michael Silverman
Journal:  JAMA Netw Open       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.